- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06686394
Étude sur le Patritumab Deruxtecan avec d'autres agents anticancéreux chez des participantes atteintes d'un cancer du sein HER2 positif qui s'est propagé et ne peut pas être retiré chirurgicalement (MK-1022-009)
HERTHENA-Breast-01 : Une étude de phase 1b/2, multicentrique, ouverte, de recherche de dose pour évaluer l'innocuité et l'activité antitumorale du Patritumab Deruxtecan chez les participantes atteintes d'un cancer du sein localement avancé non résécable HER2 positif ou d'un cancer du sein métastatique
Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain breast cancers. The breast cancers being studied are HER2 positive unresectable locally advanced or metastatic (the cancer has spread to other parts of the body). The goals of this study are to learn:
- About the safety and how well people tolerate of patritumab deruxtecan
- How many people have the cancer respond (get smaller or go away) to treatment
Aperçu de l'étude
Statut
Les conditions
Description détaillée
The following countries will be participating in the trial: Canada, United Kingdom, Israel, Japan, South Korea, and USA.
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: Toll Free Number
- Numéro de téléphone: 1-888-577-8839
- E-mail: Trialsites@msd.com
Lieux d'étude
-
-
Ontario
-
Kingston, Ontario, Canada, K7L 2V7
- Recrutement
- Kingston General Hospital ( Site 0061)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 6135336541
-
Toronto, Ontario, Canada, M5G 2M9
- Recrutement
- Princess Margaret Cancer Centre ( Site 0001)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 416-946-4501
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1E2
- Recrutement
- Jewish General Hospital ( Site 0003)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 514-340-8222
-
Montreal, Quebec, Canada, H2X 3E4
- Recrutement
- Centre Hospitalier de l'Université de Montréal ( Site 0004)
-
Contact:
- Study Coordinator
- Numéro de téléphone: (514)890-8000 x20737
-
-
-
-
-
Seoul, Corée du Sud, 03080
- Recrutement
- Seoul National University Hospital ( Site 0030)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 82-2-2072-0850
-
Seoul, Corée du Sud, 05505
- Recrutement
- Asan Medical Center ( Site 0031)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +82-2-1688-7575
-
-
-
-
-
Haifa, Israël, 3109601
- Recrutement
- Rambam Health Care Campus ( Site 0011)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 04-7776234
-
Petah Tikva, Israël, 4941492
- Recrutement
- Rabin Medical Center ( Site 0012)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +972-505533121
-
Ramat Gan, Israël, 5265601
- Recrutement
- Sheba Medical Center ( Site 0010)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 03-5304498
-
-
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japon, 467-8602
- Recrutement
- Nagoya City University Hospital ( Site 0020)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +81-52-851-5511
-
-
-
-
Camden
-
London, Camden, Royaume-Uni, NW1 2PG
- Recrutement
- University College London Hospital ( Site 0041)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +442034472930
-
-
Glasgow City
-
Glasgow, Glasgow City, Royaume-Uni, G12 0YN
- Recrutement
- The Beatson West of Scotland Cancer Centre ( Site 0043)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +441413017000
-
-
London, City of
-
London, London, City of, Royaume-Uni, EC1A 7BE
- Recrutement
- St Bartholomew s Hospital ( Site 0040)
-
Contact:
- Study Coordinator
- Numéro de téléphone: +442073777000
-
-
-
-
Colorado
-
Aurora, Colorado, États-Unis, 80045
- Recrutement
- University of Colorado Anschutz Medical Campus ( Site 0057)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 720-848-1030
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02215
- Recrutement
- Dana-Farber Cancer Institute ( Site 0050)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 877-338-7425
-
-
New Jersey
-
New Brunswick, New Jersey, États-Unis, 08901
- Recrutement
- Rutgers Cancer Institute of New Jersey ( Site 0052)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 732-235-2465
-
-
South Carolina
-
Greenville, South Carolina, États-Unis, 29605
- Recrutement
- Prisma Health - Upstate (ITOR)_Edenfield ( Site 0053)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 864-455-3600
-
-
Virginia
-
Fairfax, Virginia, États-Unis, 22031
- Recrutement
- Inova Schar Cancer Institute ( Site 0051)
-
Contact:
- Study Coordinator
- Numéro de téléphone: 571-472-4724
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
The main inclusion criteria include but are not limited to the following:
- Has histologically confirmed HER2+ locally advanced unresectable breast cancer or metastatic breast cancer
- Human immunodeficiency virus (HIV)-infected participants must have well-controlled HIV on antiretroviral therapy (ART)
- Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received HBV antiviral therapy for at least 4 weeks, and have undetectable hepatitis B virus (HBV) viral load before allocation
- Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable
- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 within 7 days before start of study intervention
Part 1 Arm 1:
- Has received at least a minimum of 2 and a maximum of 5 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting
- Had disease progression on or after any previous trastuzumab deruxtecan (T-DXd) treatment
Part 1 Arm 2:
-Has received no more than 5 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting
Part 1 Arm 3:
-Has received and had disease progression from T-DXd treatment in any setting and a maximum of 3 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting. T-DXd must be the most recent therapy received before enrollment.
Part 2 : Has not received prior systemic therapy (including T-DXd) for recurrent locally advanced or metastatic breast cancer (mBC).
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
- Uncontrolled or significant cardiovascular disease
- Has any history of (noninfectious) interstitial lung disease (ILD)/ pneumonitis irrespective of steroid use or has current ILD or suspected ILD
- Has clinically severe respiratory compromise
- Has any history of or evidence of any current leptomeningeal disease
- Has clinically significant corneal disease
- Evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection
- HIV infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
- Known additional malignancy that is progressing or has required active treatment within the past 3 years
- Part 1: Evidence of spinal cord compression or brain metastases
- Part 2: Evidence of spinal cord compression or brain/CNS metastases.
- Has an active infection requiring systemic therapy
- Concurrent active HBV and HCV infection
- Has had major surgical procedure (excluding placement of vascular access) less than 28 days
Part1: Arm 3 ONLY
- Has received prior treatment with tucatinib, lapatinib, or neratinib, or any investigational HER2-targeted tyrosine kinase inhibitors in the locally advanced or metastatic setting
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation séquentielle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Part 1: Patritumab deruxtecan plus trastuzumab
Participants receive patritumab deruxtecan intravenous (IV) infusion and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision. |
Patritumab deruxtecan administered via IV infusion
Autres noms:
Trastuzumab administered via IV infusion
Autres noms:
Trastuzumab biosimilar administered via IV infusion
Autres noms:
|
|
Expérimental: Part 1: Patritumab deruxtecan plus pertuzumab and trastuzumab
Participants receive patritumab deruxtecan IV infusion, pertuzumab IV infusion, and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision. |
Patritumab deruxtecan administered via IV infusion
Autres noms:
Trastuzumab administered via IV infusion
Autres noms:
Trastuzumab biosimilar administered via IV infusion
Autres noms:
Pertuzumab administered via IV infusion |
|
Expérimental: Part 1: Patritumab deruxtecan plus trastuzumab and tucatinib
Participants receive patritumab deruxtecan IV infusion and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks), and tucatinib is administered orally twice daily for each 21-day cycle, until disease progression, intolerable toxicity, or investigator decision. |
Patritumab deruxtecan administered via IV infusion
Autres noms:
Trastuzumab administered via IV infusion
Autres noms:
Trastuzumab biosimilar administered via IV infusion
Autres noms:
Tucatinib administered as oral tablets |
|
Expérimental: Part 2: Patritumab deruxtecan plus pertuzumab and trastuzumab
Participants receive patritumab deruxtecan IV infusion, pertuzumab IV infusion, and trastuzumab or trastuzumab biosimilar IV infusion on Day 1 of each 21-day cycle (every 3 weeks) until disease progression, intolerable toxicity, or investigator decision. |
Patritumab deruxtecan administered via IV infusion
Autres noms:
Trastuzumab administered via IV infusion
Autres noms:
Trastuzumab biosimilar administered via IV infusion
Autres noms:
Pertuzumab administered via IV infusion |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Part 1: Number of Participants Experiencing Dose-Limiting Toxicity (DLT)
Délai: Up to 21 days
|
DLT will be defined as any drug-related AE observed during the DLT evaluation period that results in a change to a given dose or a delay in initiating the next cycle. The number of participants who experience a DLT will be presented. |
Up to 21 days
|
|
Part 1: Number of Participants with One or More Adverse Events (AEs)
Délai: Up to approximately 36 months
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented. |
Up to approximately 36 months
|
|
Part 1: Number of Participants who Discontinue Study Intervention Due to an AE
Délai: Up to approximately 12 months
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinue study treatment due to an AE will be presented. |
Up to approximately 12 months
|
|
Part 2: Objective Response Rate (ORR)
Délai: Up to approximately 36 months
|
ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR)will be presented. |
Up to approximately 36 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Part 1: Maximum Plasma Concentration (Cmax) of Patritumab Deruxtecan Antibody-Drug Conjugate (ADC)
Délai: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Cmax of patritumab deruxtecan ADC. |
At designated time points (up to ~13 months)
|
|
Part 1: Trough Concentration (Ctrough) of Patritumab Deruxtecan ADC
Délai: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Ctrough of patritumab deruxtecan ADC. |
At designated time points (up to ~13 months)
|
|
Part 1: Area Under the Plasma Concentration-Time Curve (AUC) of Patritumab Deruxtecan ADC
Délai: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the AUC of patritumab deruxtecan ADC. |
At designated time points (up to ~13 months)
|
|
Part 1: Maximum Plasma Concentration (Cmax) of Total Patritumab Deruxtecan Antidrug Antibody (ADA)
Délai: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Cmax of total patritumab deruxtecan ADA. |
At designated time points (up to ~13 months)
|
|
Part 1: Trough Concentration (Ctrough) of Total Patritumab Deruxtecan ADA
Délai: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Ctrough of total patritumab deruxtecan ADA. |
At designated time points (up to ~13 months)
|
|
Part 1: Area Under the Plasma Concentration-Time Curve (AUC) of Total Patritumab Deruxtecan ADA
Délai: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the AUC of total patritumab deruxtecan ADA. |
At designated time points (up to ~13 months)
|
|
Part 1: Maximum Plasma Concentration (Cmax) of Patritumab Deruxtecan Free Payload
Délai: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Cmax of patritumab deruxtecan free payload. |
At designated time points (up to ~13 months)
|
|
Part 1: Trough Concentration (Ctrough) of Patritumab Deruxtecan Free Payload
Délai: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the Ctrough of patritumab deruxtecan free payload. |
At designated time points (up to ~13 months)
|
|
Part 1: Area Under the Plasma Concentration-Time Curve (AUC) of Patritumab Deruxtecan Free Payload
Délai: At designated time points (up to ~13 months)
|
Blood samples collected at designated time points will be used to determine the AUC of patritumab deruxtecan free payload. |
At designated time points (up to ~13 months)
|
|
Part 2: Duration of Response (DOR)
Délai: Up to approximately 36 months
|
For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is alsoc onsidered PD. DOR as assessed by BICR will be presented. |
Up to approximately 36 months
|
|
Part 2: Progression Free Survival (PFS)
Délai: Up to approximately 36 months
|
PFS is defined as the time from first day of study intervention to the first documented progressive disease (PD)or death due to any cause, whichever occurs first as assessed by BICR. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR will be presented. |
Up to approximately 36 months
|
|
Part 2: Number of Participants with One or More AEs
Délai: Up to approximately 36 months
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented. |
Up to approximately 36 months
|
|
Part 2: Number of Participants who Discontinue Study Intervention Due to an AE
Délai: Up to approximately 12 months
|
An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented. |
Up to approximately 12 months
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Directeur d'études: Medical Director, Merck Sharp & Dohme LLC
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Tumeurs par site
- Tumeurs
- Maladies de la peau
- Maladies du sein
- Maladies de la peau et du tissu conjonctif
- Tumeurs mammaires
- Acides aminés, peptides et protéines
- Protéines
- Anticorps, monoclonal, humanisé
- Anticorps, monoclonal
- Anticorps
- Immunoglobulines
- Immunoprotéines
- Protéines sanguines
- Globulines sériques
- Globulines
- Trastuzumab
- pertuzumab
- tucatinib
- Patritumab Deruxecan
- Ogivri
- Ontruzant
Autres numéros d'identification d'étude
- 1022-009
- MK-1022-009 (Autre identifiant: MSD)
- jRCT2041250022 (Identificateur de registre: Japan Registry of Clinical Trials (jRCT))
- 2026-528266-19 (Identificateur de registre: EU CT)
- U1111-1346-4321 (Identificateur de registre: UTN)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .